Nadege Morisot
Director, In Vivo Translational Biology Earli
Dr. Nadege Morisot is Director of In Vivo Translational Biology at Earli Inc., advancing a novel cancer therapy platform combining synthetic gene regulation, gene therapy, and LNP-mRNA delivery to transform tumors into therapeutic protein factories. She leads preclinical development across multiple cancer indications, managing diverse model pipelines from in vitro systems through non-human primate studies to assess translatability. With extensive expertise in in vivo pharmacology, PK/PD assessment, and regulatory compliance, Dr. Morisot has successfully translated her preclinical R&D experience across therapeutic areas including oncology, neurodegeneration, and metabolic disorders, driving innovative approaches in drug discovery and development.
Seminars
- Utilizing a comprehensive multi-omics analysis of cancer and healthy patient’ tissues to design novel tumor-selective synthetic promoters for non-viral therapeutic protein expression
- Validating highly specific and cancer-activated vector expression across diverse PDX models, robustly addressing patient population heterogeneity
- Demonstrating tumor-tropic delivery of engineered nanoparticles, resulting in improved efficacy of expressed immune-modulators in a comprehensive panel of in vivo cancer models
